Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by whisky11on Apr 28, 2021 9:48am
137 Views
Post# 33081540

RE:RE:Reverse split is a necessity

RE:RE:Reverse split is a necessityzardoz00]It might be but in 90% of the cases independently of the value of the company, after a reverse split the shares go down as the predative shorters go into action.  So, I will sell before the RS, wait for the price to drop and buy back at a better price.  If I’m wrong then so be it.

whisky11: if you're wrong at least you can use it as a lesson for future investment.
Why don't you start from  reading last interview with R.Farrell
He explained that reverse split will be done  at the same time  PR's will be released. So I can imagine from one million shares next morning I have 100,000 shares. But then there is an announcement that the bankers want to invest $20 million in Claritas and the US government approved Application for $60 million to cover expenses with faze 2and3
And they announce that the governments wants to expedite approval because of the importance to save peoples life.
In case like that, more shorts then better. Personally I don't care how many zeros is in the number of my shares ,the dollar value that's what's matter
<< Previous
Bullboard Posts
Next >>